Advancing ADC Development: End-to-End Solutions from Design to Characterisation
Supported by:
11 June 2025
3:00pm
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Join Dr Francisca Neethling from Eurofins Discovery to explore the comprehensive process of ADC development, covering payload linker design, optimisation, and the bioanalytical and functional characterisation of ADC molecules.
ADC (Antibody-Drug Conjugate) drug discovery is a specialized approach in pharmaceutical research and development that focuses on creating targeted therapies. ADCs combine the targeting ability of monoclonal antibodies with the cell-killing power of cytotoxic drugs. The goal is to deliver a potent drug directly to the target cells while minimizing damage to healthy surrounding tissue.
Developing an Antibody-Drug Conjugate (ADC) is a complex process that requires careful consideration of several key factors to ensure efficacy, safety, and manufacturability.
Here are the main factors that need to be considered, including:
- Antibody selection
- Cytotoxic drug selection
- Linker chemistry
- Conjugation chemistry
Key learning points:
- How ADCs are advancing in the Drug Discovery landscape
- How monoclonal antibodies and cytotoxic drugs are conjugated and optimised to revolutionise the cancer treatment world
- How ADCs can reduce damage to healthy tissue, leading to improved patient experience and long-term outcomes
- How to characterise ADCs to determine potential efficacy, MOA and safety to predict clinical outcomes with more accuracy.
Register your details today >>>
OUR SPEAKER
Dr Francisca Neethling – Head of Biotherapeutic Services, Eurofins Discovery
Dr Francisca Neethling, is the Head of Biotherapeutics Discovery at Eurofins Discovery. She brings over 20 years of academic, start-up and pharmaceutical Industry experience to support portfolio and program strategy for large molecule drug discovery.
DrNeethling holds a B.Sc. in Microbiology and Genetics and a M.Sc. and Ph.D. in Transplantation Immunology. She was a Postdoctoral Fellow at the Transplantation Biology Research Centre at Harvard Medical School and at Oklahoma State University. Prior to joining Eurofins Discovery in 2021, Dr. Neethling spent almost 10 years as a Sr. Principal Scientist in the antibody discovery group at Boehringer Ingelheim, developing novel biologics across a broad range of therapeutic areas.
FAQs
Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.
When will the webinar take place?
The webinar will take place live on 11 June at 8am Pacific Time / 4pm BST
I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
During the live webinar, you’ll be able to ask the speakers your questions, which will then be answered during the live Q&A session towards the end of the webinar.
How long will the webinar be?
This webinar will last for up to one hour.
What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.
Do I receive a certificate?
Yes, you will receive a certificate if you attend the webinar live. The certificate will be sent with your on-demand video link.
